Is Israel Banning Smoked Medical Cannabis? The 2026 Proposal Explained

In May 2026 headlines around the world announced that Israel was banning smoked medical cannabis. The reality is more complicated, and for the roughly 140,000 Israelis the Health Ministry counts as licence holders it matters a great deal: a Health Ministry committee recommended a three-year phase-out — and three days later the health minister froze the whole thing. Nothing has changed for patients yet. This guide explains what was proposed, why, who objected, and what to watch next.

This guide is informational and is not medical advice. Do not change how you take a prescribed treatment without speaking to your prescribing physician.

What the committee actually recommended

On Sunday 3 May 2026, a special Health Ministry committee on medical cannabis published its conclusions. The headline item: an end to the use and marketing of medical cannabis for smoking within three years, with patients moved instead onto extracts (oils) or precision inhalers, on the grounds of health risk and inconsistent absorption (Times of Israel).

The committee was chaired by Dr. Gilad Bodenheimer, head of the ministry's mental health division. Its remit was framed as reducing risk and improving safety rather than restricting access for its own sake, and the smoking clause was only one of several recommendations. The package also included:

• Moving dispensing to the HMOs. Within about a year, responsibility for medical cannabis would shift from the Health Ministry's Medical Cannabis Unit (the "Yakar") to the health funds, so that the treating physician has full access to the patient's medical record (Times of Israel).
• Harder renewals. Renewing a prescription beyond six months would require an actual meeting with the prescribing physician rather than a paper renewal.
• Tighter PTSD criteria. Cannabis for PTSD would be limited to severe distress — insomnia, agitation, flashbacks — and only alongside proven psychotherapy.
• Lower THC concentrations in dispensed products, alongside the shift in format (ICBC, citing the Jerusalem Post).
• Professional and safety measures. Mandatory training for prescribing clinicians, stricter reporting around driving and firearms eligibility, and expanded investment in clinical research (StratCann).

Exceptions would be allowed in limited clinical cases, under strict supervision and dosage limits (ICBC, citing the Jerusalem Post); one trade report describes those carve-outs as covering patients over 75 and the terminally ill (Hemp Gazette), though the ministry's own published summaries do not specify an age.

Why the ministry wanted to move

The case rests on how fast, and in what direction, the programme has grown. Licence numbers rose from about 33,000 in 2019 to roughly 140,000 in 2025, with the sharpest increase among men and people under 45 (Times of Israel). Of the data presented to the committee, three figures did most of the persuading: 62% of patients consume more than 30 grams a month, high-THC preparations appear in about 88% of licences, and consumption by smoking is close to total (Times of Israel) — roughly 87% of patients smoke (StratCann), and about 98% of licensed purchases are for flower (ICBC, citing the Jerusalem Post).

One nuance the headline growth figure hides: the peer-reviewed count that underpins it puts the peak at 140,483 active licences in January 2024, followed by a decline of roughly 7.5% to about 129,900 by March 2025 — the programme's first contraction since 2011, driven by tighter HMO gatekeeping (Journal of Cannabis Research, 2025). The committee was arguing about a curve that had already begun to bend.

The clinical objection to smoking is not new in Israel. The Israel Medical Association recommended in 2023 that medical cannabis be given primarily in oil form, arguing that smoking "is more typical of recreational consumption than of consumption as part of medical treatment" and that mixing cannabis with tobacco — common practice locally — drives tobacco addiction and smoking rates (Times of Israel). Add the dosing problem — you cannot know how much THC a patient actually absorbed from a joint — and regulators see a treatment administered in a way no other medicine is.

Bodenheimer put the ministry's underlying worry bluntly: "There is a widespread belief among the public that cannabis is a magic cure, and this is not the case." He cited a more than 20% risk of developing dependence, including among medical users, and told the committee the evidence base for PTSD — now about 17% of Israeli cannabis patients — is not strong enough to justify its growth.

Then the minister froze it

The recommendations were non-binding. On Wednesday 6 May 2026, three days after publication, Health Minister Haim Katz instructed the ministry's director-general to halt all work on implementing them (StratCann; Ynet).

His reasoning was explicitly patient-side: "I was not sufficiently convinced that there was justification for implementing the recommendations, given the potential harm to patients," Katz said, adding that he had personally seen "the suffering of patients who were forced to go through hardships until they received a prescription for medical cannabis." Even where tighter supervision is warranted, he argued, "going back, making the procedure cumbersome, and restricting the use of medical cannabis are not the way to go."

Industry bodies, patient groups and other politicians had already begun pushing back before the freeze. That is the shape of the fight: a public-health case for medicalising the programme properly, against a patient-access case that every added gate historically translates into people going without.

What this means for patients right now

Nothing has been banned. As of late July 2026, smokable medical cannabis remains available to licensed patients in Israel on the same terms as before, and the licensing pathway is unchanged — see how to get a medical cannabis licence in Israel for the current process.

Three practical points follow:

1. A freeze is not a repeal. The recommendations exist, they came from the ministry's own professional committee, and the direction of travel across two separate reform waves has been toward tighter, more medicalised control. A future minister, or this one under different pressure, can unfreeze them.
2. The non-smoking alternatives are already here. Oils and metered-dose inhalers are approved and dispensed in Israel today. Patients who want to get ahead of any future change can discuss the switch with their physician now rather than under a deadline.
3. PTSD patients face the sharpest exposure. The PTSD clauses were the most restrictive part of the package, and PTSD is the fastest-growing indication — see medical cannabis for PTSD in Israel for the detail.

The bottom line

Israel did not ban smoked medical cannabis in 2026. Its Health Ministry's own experts recommended doing so by 2029, its health minister stopped the process within 72 hours, and the underlying disagreement — is a 140,000-patient programme a medical system or a consumer market? — is unresolved. Expect it to return.

For the wider legal picture, see our Regulation hub and is cannabis legal in Israel?; for what access looks like in practice, start at the Patients hub.